|Bid||76.77 x 1200|
|Ask||77.43 x 900|
|Day's range||76.41 - 77.72|
|52-week range||53.22 - 78.47|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||27.32|
|Forward dividend & yield||2.16 (2.82%)|
|Ex-dividend date||31 Mar 2022|
|1y target est||N/A|
As the leader in medical diagnostics, Roche (OTC: RHHB.F) acted quickly to deliver valuable COVID-19 screening tests to the marketplace. Assisted by COVID-related sales, its diagnostics division is now delivering stronger growth than its larger pharmaceuticals division. Roche's medical diagnostics division saw strong growth throughout 2021 and into the begining of 2022.
Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.